Invivyd Advances Phase 3 VYD2311 COVID-19 Prevention Trial, Keeping Optionality Alive for Investors

Invivyd (IVVD) announced an update on their ongoing clinical study.

Invivyd’s new Phase 3 trial, officially titled “A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VYD2311 for the Prevention of COVID-19 in Adults and Adolescents,” aims to show that its antibody drug can cut the risk of getting COVID-19 in people aged 12 and older. The study matters for investors because it could position Invivyd as a key player in COVID-19 prevention for higher‑risk groups and those who do not respond well to vaccines.

The trial is testing VYD2311, an injected antibody drug designed to latch onto the virus that causes COVID-19 and block it from entering human cells. It is given as a shot into the muscle of the upper thigh or upper arm, either once or once a month for three months, with the goal of offering short‑term protection against infection.

This is an interventional Phase 3 study with participants randomly assigned to one of three groups: a single dose of VYD2311 plus later placebo shots, three monthly doses of VYD2311, or three monthly placebo shots. The design is parallel, meaning each group follows its own treatment path, and it is “triple-blind,” so participants, care teams, and study assessors do not know who gets the real drug. The main goal is to prevent COVID-19, with safety and tolerability tracked closely.

The study was first submitted in December 2025, marking the formal start of regulatory tracking and signaling Invivyd’s move into late‑stage development. The key period for measuring how well the drug works is the first 90 days after the initial shot, which will underpin the primary completion date once enough cases and follow‑up data are gathered. The overall study will run longer to collect safety and lab data, with an estimated full completion after all follow‑ups are done. The record was last updated on January 23, 2026, confirming that the trial plan and status are current and that enrollment is ongoing.

For investors, the update reinforces that Invivyd is advancing a late‑stage asset that could fill an important niche in COVID-19 prevention, especially for immune‑compromised patients and vaccine‑reluctant groups. A successful outcome could support a premium valuation given the limited number of marketed long‑acting antibodies after earlier products from AstraZeneca and others were withdrawn or lost effectiveness against new variants. However, demand will depend on how the pandemic evolves, the strength of upcoming vaccine boosters, and payer willingness to reimburse preventive antibodies. The ongoing trial status keeps optionality alive for Invivyd’s stock and may support speculative interest ahead of key data, while also reminding investors that clinical, regulatory, and uptake risks remain high.

The study is currently ongoing and recently updated, with further details available on the ClinicalTrials.gov portal under the listed identifier.

To learn more about IVVD’s potential, visit the Invivyd drug pipeline page.